Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Johnson & Johnson

Drug Profile

Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Johnson & Johnson

Alternative Names: JNJ 25918646

Latest Information Update: 11 Sep 2008

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Adamantanes
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 04 Sep 2008 Preclinical adverse events and pharmacodynamics data presented at the 20th International Symposium on Medicinal Chemistry (ISMC-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top